EANO Educational Day - Thursday, September 15, 2022
Note that the programme is subject to change and will be continuously updated. Speaker and presentation details will be published in due course.
All times below refer to Central European Summer Time (CEST).
08:55-10:00 hrs
Chairs: Evangelia Razis, Greece
EDB01.1 What is the role of the pathologist?
Sebastian Brandner, United Kingdom
EDB01.2 What makes a successful Molecular Tumor Board (MTB)?
Evangelia Razis, Greece
EDB01.3 The role of radiology in neuro-oncology?
Gerry Thompson, United Kingdom
Chairs: tba
EDC01.1 From symptom to a biomarker of tumor response to treatments, and beyond
Roberta Rudà, Italy
EDC01.2 Medical management of epilepsy in the neuro-oncological patient
Robin Grant, United Kingdom
EDC01.3 Management of glioma-related epilepsy: the importance of surgery
Johan Pallud, France
Chairs: tba
EDN01.1 How patient symptoms and caregiver wellbeing are interconnected
Florien Boele, United Kingdom
EDN01.2 The impact of medical infographics on symptom awareness and communication
Karin Piil, Denmark
EDN01.3 The impact of family-centred care on symptoms in patients with high-grade glioma
Giulia Locatelli, Italy
10:00-10:10 hrs | BREAK
10:10-11:30 hrs
Chairs: tba
EDB02.1 Neuroscience-immunology: the basics of brain immunology
tba
EDB02.2 Promises and pitfalls of cellular immunotherapies against cancer
Else Marit Inderberg, Norway
EDB02.3 Gene and viral immunotherapies
E. Antonio Chiocca, United States
chairs: tba
EDC02.1 Mechanistic mathematical models in diagnosis and trial in neuro-oncology
Victor Perez Garcia, Spain
EDC02.2 5 most important new pathology developments
Felix Sahm, Germany
EDC02.3 5 most important advances in local therapy
Stephen Price, United Kingdom
EDC02.4 Tumor board in daily practice
Riccardo Soffietti, Italy
chair: tba
EDN02.1 Patient-reported measure to enhance person-centred care
Lena Rosenlund, Sweden
EDN02.2 A patient-centred approach to the clinical conversation
Sara Melhuish, United Kingdom
EDN02.3 Stakeholder engagement: working together towards better support for carers
Emma Nicklin, United Kingdom
EDN02.4 Organisation of a person-centred clinical practice
Christina Nagl, Austria
11:30-12:00 hrs | COFFEE BREAK
12:00-13:15 hrs
chair: tba
EDB03.1 Spatial transcriptomics
Pim French, Netherlands
EDB03.2 Functional tissue profiling
Tobias Weiss, Switzerland
EDB03.3 Spatial metabolomics
Richard Mair, United Kingdom
Chairs: tba
EDC03.1 The Gliogene porject (xyndromes that predispose to brain tumors)
Melissa Bondy, United States
EDC03.2 NF1&2
João Passos, Portugal
EDC03.3 Counseling
Megan Hill, United Kingdom
Chairs: tba
EDN03.1 Development of a model to promote support for families during the course of the disease
Pernilla Ståhl, Sweden
EDN03.2 Patient-report cognitive function in patients with diffuse glioma
Stine Schei, Norway
EDN03.3 Language assessment of patients with glioma in Slovenia
Barbara Vogrinčič, Slovenia
EDN03.4 Objective measure of cognitive fatigability in low-grade gliomas patients
Valentine Facque, France
13:15-14:00 hrs | LUNCH BREAK
14:00-15:00 hrs
Chairs: tba
EDB04.1 Glioma on a chip: Miniaturized brain tumor models
tba
EDB04.2 Microfluidics-based tumor models
tba
EDB04.3 Immunocompetent ex vivo and in vivo models
Simone Niclou, Luxembourg
Chair: tba
EDC04.1 Indications and goals of physical rehabilitation
tba
EDC04.2 Indications for cognitive rehabilitation
Claudia Panciroli, Spain
EDC04.3 Differences between aphasia, dysarthria and dysphagia between stroke and glioma
Marike Donders-Kamphuis, Netherlands
15:00-15:15 hrs | BREAK
15:15-16:30 hrs
Chairs: tba
EDB05.1 CTCs: New Translational Dimensions to Study Brain Metastasis
Dario Marchetti, United States
EDB05.2 Liquid biopsies: ctDNA in brain tumor patient
Florent Mouliere, Netherlands
EDB05.3 Imaging biomarkers for brain metastasis
Rasheed Zaharia, United Kingdom
EDB05.3 Radiomics and AI in Neuro-Oncology
tba
Chairs: tba
EDC05.1 Rehabilitation guidelines
Richard Crevenna, Austria
EDC05.2 LM guidelines
Emilie Le Rhun, Switzerland
EDC05.3 Complications of neuro-oncology therapy
Michael Wellner, Switzerland
EDC05.4 Molecular biomarkers
David Capper, Germany
Chairs: tba
EDN04.1 It's all in my head: lessons from survivorship
Rachael Simms-Moore, United Kingdom
EDN04.2 Patient, next of kin and public involvement in clinical routine and research - an example from Stockholm, Sweden
Eskil Degsell, Sweden
EDN04.3 RTT led SRS clinic for patients with brain mets?
Aoife Williamson, United Kingdom
EDN04.4 Closing remarks
Florien Boele, United Kingdom
EANO Meeting - Thursday, September 15, 2022
17:00-18:00 hrs
Chairs: tba
PC01.1 Re-irradiation of brain tumors: Pro arguments
Elizabeth Cohen-Jonathan Moyal, France
PC01.2 Re-irradiation of brain tumors: Con arguments
Fréderic Dhermain, France
Chairs: tba
PD01.1 Economic evaluation of diagnostic tests
Bethany Shinkins, United Kingdom
PD01.2 Radiotherapy and systemic therapies
Katie Spencer, United Kingdom
PD01.3 Vocational and economic patient outcomes
Isabelle Ryden, Sweden
Chairs: tba
JS01.1 Impact of microglia and other immune cells on glioblastoma progression and second-line treatment
Sven Nelander, Sweden
JS01.2 Overview of ongoing clinical trials for recurrent gliomas in China
Zhongping CHEN, China
